Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches.

Area of Science:

• Biomedical research
• Genomics
• Drug discovery

Background:

• Heart failure (HF) is a complex condition with increasing prevalence and significant mortality.
• The diverse causes and molecular underpinnings of HF pose challenges for effective therapy development.

Purpose of the Study:

• To review how multi-omics approaches can enhance heart failure drug discovery and development.
• To explore the application of omics in target selection, preclinical studies, and clinical trials.

Main Methods:

• Review of current literature on omics technologies in heart failure research.
• Analysis of how genomics, proteomics, transcriptomics, metabolomics, and epigenomics contribute to understanding HF.
• Integration of multi-omics data across the drug development pipeline.

Main Results:

• Omics technologies have advanced the understanding of HF at a molecular level.
• New biomarkers and therapeutic targets for HF have been identified through omics studies.
• Omics enable personalized treatment strategies, prediction of adverse drug effects, and patient stratification.

Conclusions:

• Multi-omics integration is crucial for accelerating heart failure drug discovery.
• Personalized and more effective therapies for heart failure can be developed by applying omics approaches.
• The use of omics throughout the drug development process promises improved outcomes for HF patients.